FY2025 Earnings Estimate for SLNO Issued By HC Wainwright

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities researchers at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Soleno Therapeutics in a report issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.42 per share for the year, up from their prior forecast of $0.10. HC Wainwright currently has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q4 2025 earnings at $0.83 EPS, Q1 2026 earnings at $0.88 EPS and FY2026 earnings at $4.82 EPS.

Other equities analysts also recently issued reports about the company. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. The Goldman Sachs Group set a $125.00 target price on Soleno Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $114.00 price objective (up previously from $106.00) on shares of Soleno Therapeutics in a report on Tuesday. Finally, Zacks Research raised shares of Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $110.62.

Soleno Therapeutics Price Performance

Shares of SLNO stock opened at $43.56 on Thursday. The firm has a fifty day moving average of $47.32 and a two-hundred day moving average of $61.69. The firm has a market cap of $2.34 billion, a P/E ratio of -23.67 and a beta of -3.12. Soleno Therapeutics has a 1-year low of $39.43 and a 1-year high of $90.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The company had revenue of $66.02 million for the quarter, compared to analyst estimates of $47.46 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the period. Goldman Sachs Group Inc. grew its holdings in Soleno Therapeutics by 50.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock worth $45,236,000 after buying an additional 213,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Soleno Therapeutics by 48.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock valued at $2,909,000 after acquiring an additional 13,211 shares during the period. Avior Wealth Management LLC raised its stake in Soleno Therapeutics by 34.9% during the 2nd quarter. Avior Wealth Management LLC now owns 4,601 shares of the company’s stock valued at $385,000 after acquiring an additional 1,191 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its position in Soleno Therapeutics by 62.8% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 7,000 shares of the company’s stock worth $586,000 after acquiring an additional 2,700 shares during the period. 97.42% of the stock is owned by institutional investors and hedge funds.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.